People: Repros Therapeutics Inc (RPRX.PH)
RPRX.PH on Philadelphia Stock Exchange
16.17USD
3:27pm EDT
16.17USD
3:27pm EDT
Price Change (% chg)
$-0.48 (-2.88%)
$-0.48 (-2.88%)
Prev Close
$16.65
$16.65
Open
$16.72
$16.72
Day's High
$16.72
$16.72
Day's Low
$16.17
$16.17
Volume
400
400
Avg. Vol
--
--
52-wk High
--
--
52-wk Low
--
--
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Nola Masterson |
65 | 2009 | Independent Chairman of the Board |
Joseph Podolski |
64 | 2009 | President, Chief Executive Officer, Director |
Katherine Anderson |
54 | 2011 | Chief Financial Officer, Chief Accounting Officer, Secretary |
Jaye Thompson |
47 | 2013 | Senior Vice President - Clinical and Regulatory |
Ronald Wiehle |
63 | Vice President - Research & Development | |
Saira Ramasastry |
2013 | Director | |
Daniel Cain |
66 | 2008 | Independent Director |
Michael Wyllie |
61 | 2011 | Independent Director |
Biographies
| Name | Description |
|---|---|
Nola Masterson |
Ms. Nola E. Masterson serves as an Independent Chairman of the Board of Repros Therapeutics Inc. She was elected a director in 2004 and became chair of the board in 2009. Since 1982, she has been the chief executive officer of Science Futures Inc., an investment and advisory firm. Ms. Masterson is currently Managing Member and General Partner of Science Futures LLC, I and II, which are venture capital funds invested in life science funds and companies. She is on the board of directors of Generex Biotechnology, Inc. (OTC BB: GNBT.OB), a Delaware corporation with headquarters in Toronto and a subsidiary in Worchester, Massachusetts. She serves on the audit committee, nominating committee and the compensation committee for Repros Therapeutics Inc. Ms. Masterson was the first biotechnology analyst on Wall Street, working with Drexel Burnham Lambert and Merrill Lynch and is a co-founder of Sequenom, Inc., a genetic analysis company located in San Diego and Hamburg, Germany. Ms. Masterson is the Chair Emeritus of the Bay Bio Institute, a 501(c) 3 part of BayBio, which promotes science education, workforce development and best practices as well as entrepreneurs in the bioeconomy. Ms. Masterson began her business career at Ames Company, a division of Bayer and spent eight years at Millipore Corporation in sales and sales management. Ms. Masterson has 33 years of experience in the life science industry. She received her Masters in Biological Sciences from George Washington University and continued Ph.D. work at the University of Florida. |
Joseph Podolski |
Mr. Joseph S. Podolski serves as President, Chief Executive Officer and Director of Repros Therapeutics Inc. Mr. Podolski has served as Chief Executive Officer and as a director since 1992. He joined the company in 1989 as Vice President of Operations. Previously, Mr. Podolski spent twelve years in various engineering, product development and manufacturing positions at G.D. Searle, a subsidiary of Monsanto Company. Before joining Monsanto, Mr. Podolski held positions in manufacturing, engineering, quality control and development of fine chemicals, antibiotics, pharmaceuticals and hospital products with Abbott Laboratories, Dearborn Chemical Company and Baxter Pharmaceuticals. Mr. Podolski holds a B.S. degree in chemistry and a M.S. degree in chemical engineering from the Illinois Institute of Technology. |
Katherine Anderson |
Ms. Katherine A. Anderson, CPA, serves as Chief Financial Officer, Chief Accounting Officer, Secretary of Repros Therapeutics Inc., Ms. Anderson originally joined the company in 2002 as an independent contractor controller and, effective October, 2009, assumed the additional position of Chief Accounting Officer. She has been Chief Financial Officer since August, 2011. Ms. Anderson is a certified public accountant with 29 years of experience in accounting and finance. Ms. Anderson earned a B.S. degree in accounting from The University of Houston. |
Jaye Thompson |
Dr. Jaye L. Thompson, Ph.D., has been appointed as Senior Vice President - Clinical and Regulatory of Repros Therapeutics Inc., effective March 26, 2013. She is no longer Director of Company effective Company’s 2013 Annual General Meeting. Dr. Jaye Thompson was elected a director in 2009. Ms. Thompson has more than 20 years of experience in the clinical research industry. She was most recently the Senior Vice President of Clinical Development and Regulatory Affairs with Opexa Therapeutics, Inc. Prior to joining Opexa, she was the Senior Vice President for Regulatory Affairs and Emerging Biotechnologies at inVentiv Clinical Solutions, LLC, a wholly-owned subsidiary of inVentiv Heatlh (NASDAQ: VTIV), a full-serve contract research organization. Prior to its acquisition by inVentiv in 2006, Dr. Thompson was President and Founder of SYNERGOS, Inc, a contract research organization based in The Woodlands, Texas. Dr. Thompson holds a Bachelor's degree in Applied Mathematics from Texas A&M University and an MS and a PhD in Biostatistics from the University of Texas Health Science Center in Houston. She was appointed to the Texas Emerging Technology Advisory Committee and has served on the Gulf Coast Regional Center of Innovation and Commercialization Executive Board, the MD Anderson Technology Review Committee and the BioHouston Associate Advisory Board. |
Ronald Wiehle |
Dr. Ronald Wiehle, Ph.D., serves as Vice President, Research and Development of Repros Therapeutics Inc. Dr. Wiehle originally joined the company in 1996 and now serves as the Vice President, Research and Development. Previously, he worked as an Assistant Biochemist at the IIT Research Institute in Chicago on animal models of human cancer. He has over 30 years of experience in biomedical sciences which includes projects involving male and female reproductive biology, cancer biology, virology and cell biology. Previously, Dr. Wiehle served as the lead scientist for all of the company's hormonally-based programs and was instrumental in the licensing of a series of SPRMs from the National Institute of Health. Dr. Wiehle received a B.S., in Chemistry, from the University of Illinois at Chicago. Dr. Wiehle earned his Ph.D. in Biochemistry from The University of Louisville School of Medicine/Health Science focusing on hormone receptors in human breast cancer. He earned a post doctoral award under a Sonderesforshungsgemeinshaft (SFG) at the Institut fuer Molekularbiologie und Tumorforshung (IMT) of the Phillips University in Marburg, Germany to study the use of recombinant retrovial vectors to transform mammalian cells. He has held faculty positions at the James Graham Brown Cancer Center/University of Louisville and the Department of Obstetrics & Gynecology at the Baylor College of Medicine. He has been awarded research grants by the NIH and local and national clinical/scientific organizations. He has authored more than 25 publications and has delivered invited lectures. |
Saira Ramasastry |
Ms. Saira Ramasastry has been appointed as Director of Repros Therapeutics Inc., effective March 25, 2013. Prior to joining the Board, Ms. Ramasastry was an advisor to the Company. Since 2009 she has served as Managing Partner of Life Sciences Advisory, LLC, a life science company advisory business. From 1999 to 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Company, Inc., an investment banking firm. From 1997 to 1998, she was a financial analyst in the M&A group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry serves on the Board of Directors of Sangamo Biosciences, Inc. and Pain Therapeutics, Inc., two publicly-held biopharmaceutical companies, the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research and the Board of Directors of the American Liver Foundation. She received a B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University, Phi Beta Kappa, as well as a M. Phil. in Management Studies from the University of Cambridge. |
Daniel Cain |
Mr. Daniel F. Cain serves as an Independent Director of Repros Therapeutics Inc., since 2004. He was chair of the board of directors from 2005 to 2008. Since October 1994, Mr. Cain has provided consulting services for small businesses. Since May 2000, he has also served as acting chief executive officer of Wireless Medical, Inc., a Colorado-based medical device company. From 1969 to 1994, Mr. Cain held various positions with Miles Laboratories, Inc., Hexcel Corporation, Scripps-Miles, Inc., Synbiotics Corporation and Heska Corporation. Mr. Cain has 38 years of broad business experience including 28 years with medical companies. Sixteen of these years were with three different biotech startup companies, one of which he co-founded. Mr. Cain has held a wide variety of executive level management positions including chief executive officer, president and chief financial officer. Mr. Cain earned a B.S. degree from LeTourneau College and a M.B.A. degree from Indiana University. |
Michael Wyllie |
Dr. Michael G. Wyllie, Ph.D., DSC., serves as an Independent Director of Repros Therapeutics Inc., since October 27, 2011. Dr. Wyllie has over 30 years of experience in senior management positions in the pharmaceutical industry. He is a director and founder of Global Pharma Consulting and is a graduate of the University of Aberdeen. While Director of Biology at Pfizer, he was involved in the discovery, development, regulatory filing and marketing of eight major pharmaceutical products including doxazosin (Cardura), darifenacin (Enablex) and sildenafil (Viagra). Subsequently, Dr. Wyllie has been involved in founding several start-up companies and the listing of four of these on the London Stock Market. He is founder and Chief Scientific Officer of Plethora Solutions, Plc, which has a product, PSD502, undergoing regulatory review in the EU for premature ejaculation. He is Chairman of Glycomar Ltd, the Oban-based marine biotechnology company and a member of the Clinical Trials Committee for the International Consultation in Sexual Medicine. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Nola Masterson |
-- |
Joseph Podolski |
1,106,240 |
Katherine Anderson |
335,870 |
Jaye Thompson |
-- |
Ronald Wiehle |
330,094 |
Saira Ramasastry |
-- |
Daniel Cain |
-- |
Michael Wyllie |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Nola Masterson |
0 | 0 |
Joseph Podolski |
723,513 | 1,062,158 |
Katherine Anderson |
0 | 0 |
Jaye Thompson |
0 | 0 |
Ronald Wiehle |
0 | 0 |
Saira Ramasastry |
0 | 0 |
Daniel Cain |
0 | 0 |
Michael Wyllie |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
PERCEPTIVE ADVISORS L L C |
50,000 | $12.50 |
PERCEPTIVE ADVISORS L L C |
150,000 | $15.00 |
PERCEPTIVE ADVISORS L L C |
150,000 | $12.50 |
PERCEPTIVE ADVISORS L L C |
400,000 | $12.50 |
PERCEPTIVE ADVISORS L L C |
50,000 | $10.00 |
PERCEPTIVE ADVISORS L L C |
50,000 | $10.00 |
PERCEPTIVE ADVISORS L L C |
50,000 | $12.50 |
PERCEPTIVE ADVISORS L L C |
100,000 | $12.50 |
PERCEPTIVE ADVISORS L L C |
50,000 | $12.50 |
PERCEPTIVE ADVISORS L L C |
100,000 | $10.00 |
PERCEPTIVE ADVISORS L L C |
100,000 | $10.00 |
PERCEPTIVE ADVISORS L L C |
400,000 | $12.50 |
PERCEPTIVE ADVISORS L L C |
200,000 | $12.50 |
PERCEPTIVE ADVISORS L L C |
100,000 | $12.50 |
PERCEPTIVE ADVISORS L L C |
100,000 | $12.50 |
ANDERSON KATHERINE A |
1,000 | $11.89 |
WYLLIE MICHAEL G |
1,068 | $13.83 |
WYLLIE MICHAEL G |
3,333 | $4.43 |
WYLLIE MICHAEL G |
9,999 | $4.43 |
MASTERSON NOLA E |
1,250 | $14.84 |
WYLLIE MICHAEL G |
2,905 | $15.25 |
MASTERSON NOLA E |
10,645 | $15.27 |
MASTERSON NOLA E |
10,000 | $14.40 |
PERCEPTIVE ADVISORS L L C |
59,500 | $7.38 |
PERCEPTIVE ADVISORS L L C |
25,000 | $6.35 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
